Jazz to Highlight Narcolepsy and IH Research at AAN 2024
The research includes an oral presentation revealing that individuals with idiopathic hypersomnia experienced higher odds of comorbid conditions, such as cardiovascular disease.
The research includes an oral presentation revealing that individuals with idiopathic hypersomnia experienced higher odds of comorbid conditions, such as cardiovascular disease.
The FDA has granted priority review to Harmony Biosciences' supplemental New Drug Application for Wakix for treating excessive daytime sleepiness or cataplexy in children aged 6 and older with narcolepsy.
New research has found that a sleep disorder thought to be rare may be as common as some other neurologic and psychiatric conditions such as epilepsy, bipolar disorder, and schizophrenia.
In its third-quarter business update, Zevra Therapeutics Inc designated KP1077, its investigational drug in development for idiopathic hypersomnia and narcolepsy, as a pivotal focus area.
Topline results from the INTUNE study of pitolisant for idiopathic hypersomnia revealed that the primary endpoint for excessive daytime sleepiness did not achieve statistical significance against a placebo in the randomized withdrawal phase.
A new study found that 85% of active duty servicemen and servicewomen have sleep disorders.
Harmony Biosciences has chosen the newest recipients of its Patients at the Heart and Progress at the Heart awards, offering financial backing to projects tackling issues faced by those with sleep disorders and rare neurological conditions.